E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Alzheimer's Disease (AD) is a brain disease that slowly destroys brain cells and has its worst effects on the areas of the brain that control memory, language, and thinking skills. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10001896 |
E.1.2 | Term | Alzheimer's disease |
E.1.2 | System Organ Class | 100000004852 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the long-term safety and tolerability of RVT-101 |
|
E.2.2 | Secondary objectives of the trial |
To assess the effects of RVT-101 on subject dependency as measures by the dependence scale (DS)
To assess the effects of RVT-101 on quality of life as measured by the EuroQOL 5 dimensions questionnaire (EQ-5D) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subjects eligible for enrollment in the study must meet all of the following criteria:
- Male or female subjects who have completed the last on-treatment visit (V8) of lead-in study RVT-101-3001.
- Subject remains on donepezil at the current stable dose for at least the first 4 weeks of this study; changes in donepezil dose and/or use of alternate background therapy during the first 4 weeks may be made only after approval by the Medical Monitor
- Female subjects must be:
a.Of non-childbearing potential or surgically sterile
b.If pre-menopausal or menopausal for 1 year or less, must have a negative pregnancy test and must not be lactating at the Screening and Baseline Visits. Female subjects of childbearing potential and who are sexually active are required to practice highly effective methods of birth control during the course of the study and until the completion of the follow-up visit.
- Male subjects who are sexually active will be required to use an adequate form of birth control including at least 1 barrier method
- Subject continues to be able to ingest pills (in tablet form) whole.
- Subject has provided full written informed consent prior to the performance of any protocol-specified procedure; or if unable to provide informed consent due to cognitive status, subject has provided assent and a legally acceptable representative has provided full written informed consent on behalf of the subject.
- Subject is able to comply with the study procedures in the opinion of the Investigator.
- General health status is acceptable for participation in this study.
- Confirmation is provided of appropriate oversight of subject's background and concomitant therapy and reliable adverse event reporting by subject and/or caregiver
- Caregiver has provided full written informed consent, on a separate informed consent form, on his/her own behalf prior to the performance of any protocol-specified procedure. Every effort should be made to have the same caregiver as in the lead in study and throughout this study.
|
|
E.4 | Principal exclusion criteria |
A subject will be excluded from participation in this study if any of the following criteria apply:
- Subject experienced an uncontrolled AE in the lead-in study that would preclude continuation in a 12-month open label extension study, in the opinion of the Investigator. Subjects who experienced an SAE during the lead-in study may be considered for participation in this study only after discussion with the Medical Monitor.
- Subject has a clinically significant vital signs or ECG abnormality at the end of the lead-in study, or at the Screening visit for this study, that would preclude continuation in a 12-month open label extension study, in the opinion of the Investigator.
- Subject has a clinically significant laboratory abnormality at V7 or V8 of the lead-in study, or at the Screening visit for this study, that would preclude continuation in a 12-month open label extension study, in the opinion of the Investigator. Investigators need not wait for V8 results before enrolling the subject in this study. However, any clinically significant abnormality subsequently identified from V8 of the lead-in study and/or at the Screening visit for this study will be evaluated by the Investigator for continued involvement in this study.
- Subject has developed any confounding medical or psychiatric condition that would preclude continuation in a 12-month open label extension study, in the opinion of the Investigator.
- Significant suicide risk as defined by suicidal ideation as endorsed on items 4 or 5 on the C-SSRS at Screening of this study, or clinical assessment of significant suicidal risk.
- Treatment with any concomitant medication detailed in Table 1.
- Confirmed corrected QT interval (QTc) value ≥ to 450 msec for males or ≥ 470 msec for females. Subjects with a QRS value greater than 120 msec and QTc value less than 500 msec may be eligible following discussion with the Medical Monitor.
- Subject is unable to take the investigational product as prescribed throughout the study (with assistance is acceptable).
- Subject is an immediate family member or employee of the participating investigator, any of the participating site staff, or of the sponsor study staff.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Incidence of AEs and changes in physical examinations, vital signs measurements, ECGs, clinical laboratory assessments, and C-SSRS results |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
DS score change from baseline at weeks 28 and 52
EQ-5D score change from baseline at weeks 28 and 52 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 16 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 74 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Australia |
Brazil |
Bulgaria |
Canada |
Chile |
Croatia |
Czech Republic |
France |
Germany |
Italy |
Korea, Republic of |
Poland |
Serbia |
Singapore |
Slovakia |
Spain |
Taiwan |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 1 |